MedTrace Logo

Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer

NCT07085572 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-10-06

No results posted yet for this study

Summary

This clinical trial is a single-arm, non-randomized, prospective phase II study.

The study aims to evaluate if the maintenance immunotherapy with cemiplimab in patients with AdrenoCortical Carcinoma (ACC), who obtained disease response or stabilization after first-line chemotherapy, may delay/prevent disease progression.

The study will be conducted at ASST Spedali Civili Hospital, Brescia - Italy.

Conditions

  • Adrenal Cortical Carcinoma

Interventions

DRUG

Cemiplimab

350 mg IV Q3W

Sponsors & Collaborators

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

    lead OTHER

Principal Investigators

  • Alfredo Berruti, Prof, MD · ASST Spedali Civili di Brescia and University of Brescia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-18
Primary Completion
2028-07-31
Completion
2028-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07085572 on ClinicalTrials.gov